Obinutuzumab (anti-CD20) | CD markers | Read Reviews & Product Use Citations

Obinutuzumab (anti-CD20) (Gazyva, GA101, Gazyvaro, Afutuzumab) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed for lymphocytic leukaemia and lymphoma of B-cell origin. MW : 146.1 kD.

Click to purchase the isotype control of

Quality Control

Batch: A202301 Purity: 99.65% Protein concentration: 5 mg/ml Endotoxin Level: ≤1 EU/mg

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

99.65

Specificity

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Obinutuzumab (anti-CD20) (Gazyva, GA101, Gazyvaro, Afutuzumab) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed for lymphocytic leukaemia and lymphoma of B-cell origin. MW : 146.1 kD.
In vitro	GA101 is the first Fc-engineered, type II humanised IgG1 antibody against CD20. Relative to rituximab, GA101 has increased direct and immune effector cell-mediated cytotoxicity and exhibits superior activity in cellular assays and whole blood B-cell depletion assays.
Cell Research	Objective: Annexin V/PI FACS assay Cells: NHL cell lines Concentrations: 10 μg/mL Incubation Time: 36 hr Method: For CD40 stimulation of hCD20 cells from transgenic mice, red blood cells (RBCs) are removed by hypotonic ammonium-chloride-potassium (ACK) lysis, and untouched splenic B cells are purified by anti-CD43–mediated depletion of non-B cells (MACS). B cells are incubated in conditioned complete RPMI 1640 medium containing 10% fetal bovine serum for 2 hours (with or without 10 μg/mL mitogenic stimulation) and either anti-CD40 or anti-IgM Fab2 antibodies. This is followed by 36 hours of anti-CD20 stimulation (GA101 or rituximab 10 μg/mL). As positive controls for the induction of cell death, the following agents are used: 100nM staurosporine for mitochondrial-mediated apoptosis, or 1 μg/mL anti-CD95 Fas for the extrinsic induction of apoptosis. Reference: https://pubmed.ncbi.nlm.nih.gov/20194898/ Obinutuzumab can apply to humanised mice (eg:SCID beige mice), peripheral blood and other related assays (Only for Reference)
In vivo	In human lymphoma xenograft models, GA101 exhibits superior anti-tumour activity, resulting in the induction of complete tumour remission and increased overall survival. In non-human primates, GA101 demonstrates superior B cell–depleting activity in lymphoid tissue, including in lymph nodes and spleen.
Animal Research	Objective: Tumour control ratio (TCR) and tumour growth inhibition (TGI) Animal Models: 4- to 8-week-old female SCID beige mice Formulation: -- Dosages: 30 mg/kg Administration: i.p. Reference: https://pubmed.ncbi.nlm.nih.gov/24304419/ Objective: NHL xenograft studies in SCID beige mice Animal Models: 4 to 5-week-old female SCID beige mice Formulation: -- Dosages: 10 mg/kg, 30 mg/kg Administration: i.p. Reference: https://pubmed.ncbi.nlm.nih.gov/20194898/ Obinutuzumab can apply to humanised mice (eg:SCID beige mice), peripheral blood and other related assays (Only for Reference)
References	[1] https://pubmed.ncbi.nlm.nih.gov/28004361/ [2] https://pubmed.ncbi.nlm.nih.gov/24304419/ [3] https://pubmed.ncbi.nlm.nih.gov/20194898/

Product Details

CAS No.	949142-50-1
Isotype	Human IgG1 isotype control
Source	Humanized (from mouse)
Sterility	0.2 μM filtered
Formulation	PBS buffer, pH 7.2
Storage	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.